Skip to content

Studying the effectiveness of herbal blends for stress and anxiety along with improved mood status in healthy individuals.

Clinical validation of safety and efficacy of herbal blends to alleviate stress and anxiety along with improved mood status in healthy individuals. - Nil

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057859
Enrollment
30
Registered
2023-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: The Blend of 4 ingredients in the ratio- Hydrolyzed Milk Protein (40%), Bacopa (40%), Piperine (10%) and Saffron (10%): 500 mg of herbal blend to be consumed with water twice a day for

Sponsors

Sush Essentials Pvt. Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects meeting all of the following criteria will be eligible for the study: 1.Healthy male or female 25-55 years of age at the time of obtaining written informed consent 2.Subjects willing to sign inform consent form 3.A female participant who is of reproductive potential has a negative pregnancy test and agrees to use contraception throughout the study period 4.Subjects are free of anti-depressants /anti-anxiety/ mood enhancing/recreational drugs intake for at least one year at the start of the screening visit 5.Subjects are free of any ‘‘over the counter’’ or prescribed medications at the start of the screening visit 6.Subjects with a score of 7-26 on the Perceived Stress Scale (PSS) 7.Willing to abstain alcohol, caffeine, and nicotine consumption while in the study 8.No reported history of psychological or mental disorders. 9.Free of psychiatric conditions other than perceived stress

Exclusion criteria

Exclusion criteria: Subjects meeting any of the following criteria will not be eligible for the study: 1.Resting systolic blood pressure above 140 mmHg or a diastolic blood pressure above 90 mmHg at baseline visit. 2.Taking any medicine or dietary supplements within the last 3 months to help to relieve sleep disturbances or physiological stress 3.History of substance abuse or dependence 4.Taking certain prohibited medications 5.Habitual smoking or vaping of products nicotine containing tetrahydrocannabinol (THC) with an average consumption >2 cigarettes or vaping more than 2 times per day 6.History of malignancy less than or equal to 5 years prior to signing an informed consent 7.Other conditions, which in the opinion of the investigators, makes the subject unsuitable for enrolment or could interfere with his/her participation in, and completion of the protocol. 8.Any known allergy or intolerance to any of the ingredients contained in supplements

Design outcomes

Primary

MeasureTime frame
Assessment of changes in- 1.Perceived stress by perceived stress scale (PSS) score questionnaire will be assessed from screening and day 21 2.Cortisol levels will be assessed at screening and day 21Timepoint: from screening and day 21

Secondary

MeasureTime frame
Assessment of changes in- 1.Measurement of mood on the POMS scale (Profile of mood state questionnaire) will be assessed from screening and day 21 2.Anxiety by using Hamilton Anxiety Rating Scale (HAM-A) score will be assessed at screening and day 21 3.Fatigue using Fatigue Severity Scale (FSS) will be assessed from screening and day 21 4.Changes in symptoms sweating, palpitations, headache, muscle pain/ body ache, fatigue, loss of appetite and irregular bowels will be assessed from screening and day 21Timepoint: from screening and day 21

Countries

India

Contacts

Public ContactMs Malvika Jain

Mprex Healthcare Pvt. Ltd.

gayatri.mbgindia@gmail.com8554912644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026